Market: NASD |
Currency: USD
Address: 11400 West Olympic Boulevard
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
📈 Immix Biopharma, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.00
-
Upside/Downside from Analyst Target:
207.02%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Immix Biopharma, Inc.
| Date | Reported EPS |
|---|
| 2025-08-08 | -0.22 |
| 2025-05-08 | -0.15 |
| 2025-03-25 | -0.15 |
| 2024-11-12 | -0.24 |
| 2024-08-12 | -0.15 |
| 2024-05-09 | -0.22 |
| 2024-03-29 | -0.24 |
| 2023-11-13 | -0.23 |
| 2023-08-11 | -0.24 |
| 2023-05-12 | -0.18 |
| 2023-03-27 | -0.27 |
📰 Related News & Research
No related articles found for "immix biopharma".
